Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis

1Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY;

2The Children's Hospital at Montefiore, Bronx, NY; and

3Faculty of Medicine, Department of Fundamental Disciplines and Clinical Prevention, Transilvania University of Brasov, Brasov, Romania.

*Address for correspondence: Professor, Faculty of Medicine, Department of Fundamental Disciplines and Clinical Prevention, Transilvania University of Brasov, 56 Nicolae Bălcescu St, 500019 Brasov, Romania. E-mail: [email protected]

The authors have no conflicts of interest to declare.

This article is part of a series evaluating drugs recently approved by the US Food and Drug Administration. The series is coordinated by Timothy Nguyen, PharmD and Kristine Willett, PharmD.

留言 (0)

沒有登入
gif